Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
As of close of business last night, Strata Critical Medical Inc’s stock clocked out at $4.65, up 0.65% from its previous closing price of $4.62. In other words, the price has increased by $0.65 from its previous closing price. On the day, 1.34 million shares were traded. SRTA stock price reached its highest trading level at $4.77 during the session, while it also had its lowest trading level at $4.47.
Ratios:
To gain a deeper understanding of SRTA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.95 and its Current Ratio is at 5.95. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Lake Street on February 26, 2025, initiated with a Buy rating and assigned the stock a target price of $6.50.
On July 18, 2023, Ladenburg Thalmann started tracking the stock assigning a Buy rating and target price of $13.
On July 17, 2023, Ladenburg Thalmann started tracking the stock assigning a Buy rating and target price of $13.Ladenburg Thalmann initiated its Buy rating on July 17, 2023, with a $13 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 04 ’25 when Tomkiel Melissa M. sold 47,995 shares for $4.94 per share. The transaction valued at 237,134 led to the insider holds 1,148,834 shares of the business.
Heyburn William A. sold 46,918 shares of SRTA for $231,822 on Aug 04 ’25. The Chief Financial Officer now owns 1,340,845 shares after completing the transaction at $4.94 per share. On Aug 04 ’25, another insider, MELISSA TOMKIEL, who serves as the Officer of the company, bought 47,995 shares for $3.78 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SRTA now has a Market Capitalization of 395855488 and an Enterprise Value of 47800060. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.49 while its Price-to-Book (P/B) ratio in mrq is 1.70. Its current Enterprise Value per Revenue stands at 0.712 whereas that against EBITDA is -1.551.
Stock Price History:
The Beta on a monthly basis for SRTA is 1.99, which has changed by 0.23860586 over the last 52 weeks, in comparison to a change of 0.13355756 over the same period for the S&P500. Over the past 52 weeks, SRTA has reached a high of $6.02, while it has fallen to a 52-week low of $2.35. The 50-Day Moving Average of the stock is -5.31%, while the 200-Day Moving Average is calculated to be 19.01%.
Shares Statistics:
It appears that SRTA traded 861.05K shares on average per day over the past three months and 635060 shares per day over the past ten days. A total of 81.70M shares are outstanding, with a floating share count of 56.76M. Insiders hold about 30.52% of the company’s shares, while institutions hold 60.67% stake in the company. Shares short for SRTA as of 1760486400 were 2386125 with a Short Ratio of 2.77, compared to 1757894400 on 2983500. Therefore, it implies a Short% of Shares Outstanding of 2386125 and a Short% of Float of 4.18.
Earnings Estimates
As of right now, 2.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $0.0, with high estimates of $0.0 and low estimates of $0.0.
Analysts are recommending an EPS of between -$0.14 and -$0.14 for the fiscal current year, implying an average EPS of -$0.14. EPS for the following year is $0.08, with 1.0 analysts recommending between $0.08 and $0.08.
Revenue Estimates
In. The current quarter, 2 analysts expect revenue to total $43.75M. It ranges from a high estimate of $44M to a low estimate of $43.5M. As of. The current estimate, Strata Critical Medical Inc’s year-ago sales were $74.88MFor the next quarter, 2 analysts are estimating revenue of $59M. There is a high estimate of $60M for the next quarter, whereas the lowest estimate is $58M.
A total of 2 analysts have provided revenue estimates for SRTA’s current fiscal year. The highest revenue estimate was $184.56M, while the lowest revenue estimate was $183.06M, resulting in an average revenue estimate of $183.81M. In the same quarter a year ago, actual revenue was $248.69MBased on 2 analysts’ estimates, the company’s revenue will be $260M in the next fiscal year. The high estimate is $270M and the low estimate is $250M.
